Profile: Karyopharm Therapeutics Inc (KPTI.O)
18 Jun 2019
Karyopharm Therapeutics Inc., incorporated on December 22, 2008, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. The Company is also engaged in the clinical development of selinexor in various solid tumor indications. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.
Selinexor is being evaluated in several mid- and later-stage clinical trials, including, among others, the Phase IIb Selinexor Treatment of Refractory Myeloma (STORM) study in multiple myeloma, the Phase Ib/II Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) study in combination with backbone therapies in multiple myeloma, the Phase IIb Selinexor Against Diffuse Aggressive Lymphoma (SADAL) study in diffuse large B-cell lymphoma (DLBCL), and the Phase II/III Selinexor in Advanced Liposarcoma (SEAL) study in liposarcoma. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.
The Company is involved in the development of a pipeline of drug candidates in both oncology, and neurological, inflammatory, autoimmune and viral indications. The Company conducts the clinical testing of oral KPT-8602, a second generation SINE compound to treat patients with relapsed/refractory multiple myeloma, and also conducts clinical testing of oral KPT-9274, a dual p21-activated kinase 4 (PAK4)/ Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in patients with lymphoma or solid tumors. KPT-350 is an investigational new drug application-ready oral compound with a preclinical data package supporting potential efficacy in a number of neuro-inflammatory conditions. Verdinexor (KPT-335) is an oral SINE compound and its lead compound that is being evaluated as a potential therapy for viral indications in addition to the canine lymphoma indication.
Karyopharm Therapeutics Inc
85 Wells Ave
NEWTON CENTER MA 02459-3298